Condition: Coronary Artery Disease · PreDiabetes · Sponsor: National Institute of Cardiology, Warsaw, Poland
The purpose of the study is to compare the anti-atherosclerotic efficacy of oral treatment with a GLP-1 analogue (semaglutide) or an SGLT-2 (so-called "flozin") inhibitor (dapagliflozin) versus routine treatment (metformin) in patients with pre-diabetes and diagnosed coronary artery disease at 24 months. The diagnosis of coronary artery disease will be defined as the presence of coronary atherosclerosis confirmed by coronary artery computed tomography (coronary CT). The study will evaluate the effect of treatment with flozin vs. semaglutide compared to treatment with metformin on the progression/regression of coronary atherosclerosis, change in plaque character, and control of cardiovascular risk factors.
This description comes directly from the study's public registry record.
Jan Henzel, MD, PhD · +48 22 343 43 42 · jhenzel@ikard.pl
Kinga Kotlinska · +48 22 343 40 88 · kkotlinska@ikard.pl
Always discuss trial participation with your own doctor first.
| National Institute of Cardiology, Department of Coronary Artery and Structural Heart Diseases | Warsaw, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07254572